OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Life sciences and health investment firm OrbiMed recently injected $8 million in Response Biomedical, a Vancouver-based company providing rapid test products based on its RAMP platform and targeting the rapid growth of China's point-of-care testing market